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Summary
We describe here the existence of a heregulin-HER3 autocrine loop, and the contribution of heregulin-dependent, HER2-
mediated HER3 activation to gefitinib insensitivity in non-small cell lung cancer (NSCLC). ADAM17 protein, a major ErbB
ligand sheddase, is upregulated in NSCLC and is required not only for heregulin-dependent HER3 signaling, but also for EGFR
ligand-dependent signaling in NSCLC cell lines. A selective ADAM inhibitor, INCB3619, prevents the processing and activation
of multiple ErbB ligands, including heregulin. In addition, INCB3619 inhibits gefitinib-resistant HER3 signaling and enhances
gefitinib inhibition of EGFR signaling in NSCLC. These results show that ADAM inhibition affects multiple ErbB pathways in
NSCLCandthusoffersanexcellentopportunity forpharmacological intervention,eitheraloneor incombinationwithotherdrugs.Introduction
The ErbB family of receptor tyrosine kinases and their ligands
are important regulators of tumor cell proliferation, angiogene-
sis, and metastasis (Gschwind et al., 2004; Yarden and Sliw-
kowski, 2001). There are four receptors in the ErbB family:
EGFR (HER1 or ErbB1), HER2 (neu or ErbB2), HER3 (ErbB3),
and HER4 (Erb4). Among them, EGFR, HER2, and HER4 have
tyrosine kinase activities; HER3 has a truncated kinase domain,
which is not functional, and thus can signal only in the context
of receptor heterodimerization (Guy et al., 1994). Eleven ligands
have been reported to bind to the ErbB receptor family, includ-
ing epidermal growth factor (EGF), transforming growth factor
a (TGFa), heparin binding EGF-like ligand (HB-EGF), amphiregu-
lin (AR), betacellulin (BTC), epiregulin (EPR), epigen (EPG), and
heregulin (HRG)/neuregulin (NRG) family members (Harris
et al., 2003). These ligands bind directly to EGFR, HER3, or
HER4, leading to the formation of hetero- or homodimers that
trigger multiple downstream signaling cascades, including
Ras-ERK and PI3K-Akt pathways (Yarden and Sliwkowski,
2001). Although HER2 lacks a functional ligand binding domain,CANCER CELL 10, 39–50, JULY 2006 ª2006 ELSEVIER INC. DOI 10.101it is the preferred partner for heterodimerization upon ligand
binding (Graus-Porta et al., 1997; Mosesson and Yarden, 2004).
While multiple ligands, including EGF, TGFa, HB-EGF, AR,
BTC, EPR, and EPG, can bind EGFR, heregulin is the only known
ligand for HER3. Heterodimerization of HER3 with HER2 results
in the formation of the most oncogenically active ErbB receptor
complex upon heregulin stimulation; coexpression of HER3 and
HER2, but not HER3 and EGFR, synergizes to transformNIH3T3
cells (Alimandi et al., 1995; Holbro et al., 2003). In addition, treat-
ment of transformed cell lines with anti-HER3 antibodies has
been shown to reduce their proliferation and migration in vitro,
in part through the alteration of HER2-HER3 dimerization (van
der Horst et al., 2005), suggesting that this pathway is important
for promoting tumorigenesis. However, the properties and clin-
ical significance of a putative autocrine mechanism involving
heregulin, HER3, and HER3’s heterodimerization partners
have not been well characterized.
ErbB ligands are structurally and functionally related mem-
brane proteins that can be proteolytically cleaved and released
from cells for signaling through autocrine and paracrine mecha-
nisms (Normanno et al., 2001; Borrell-Pages et al., 2003). ThisS I G N I F I C A N C E
Agents that inhibit EGFR function, such as gefitinib and cetuximab, have shown modest therapeutic efficacy in patients with NSCLC.
One mechanism of drug resistance is the activation of alternative ErbB pathways, such as signaling through HER3, as demonstrated
herein. Recently, ADAMs, particularly ADAM17, have emerged as upstream activators of ErbB ligands. We demonstrate here that a
selective ADAM inhibitor blocks the cleavage of multiple ErbB ligands and thereby inhibits the activation of multiple ErbB pathways,
including HER3 in NSCLC. A strategy targeting ADAMs may be an important complement to existing anti-ErbB approaches and could
be used in combination with various anti-ErbB and chemotherapeutic agents.6/j.ccr.2006.05.024 39
A R T I C L EFigure 1. Protein expression of heregulin, HER3, ADAM17, and ADAM10, and activation phosphorylation of HER3 in NSCLC tumor samples
Whole-cell extracts were prepared using tumor tissue (T) and adjacent nonmalignant lung tissue (N) from NSCLC patients (cases 1 to 14) and subjected to
SDS-PAGE and Western blot with various antibodies. b-Actin expression was used as a loading control.cleavage event is critical for the activation of the ligands under
a variety of circumstances and is thought to be mediated
by ADAMs (a disintegrin and metalloproteases) (Blobel, 2005;
Gee and Knowlden, 2003; Sahin et al., 2004; Zhou et al., 2005),
which are zinc-dependent membrane-associated metallopro-
teases. More specifically, ADAM17-deficient cells have been
shown to be defective in the shedding of TGFa, HB-EGF, EPR,
AR, and heregulin (Merlos-Suarez et al., 2001; Montero et al.,
2000; Peschon et al., 1998; Sahin et al., 2004; Sunnarborg
et al., 2002; Horiuchi et al., 2005). Although ADAM17 has been
suggested tobe themajor ErbB ligandsheddase,ADAM10 ispo-
tentially themain sheddase of EGF andBTC inmouse embryonic
fibroblasts (Sahin et al., 2004) and possibly other ligands under
specific circumstances. It is apparent that theseADAMs regulate
the availability of ErbB ligands by liberating the soluble functional
forms and, as a result, activate ErbB signaling.
Several anti-EGFR agents, including antibodies and small
molecule kinase inhibitors, have been approved recently to treat
various human cancers (Baselga and Arteaga, 2005; Herbst
et al., 2004). The chimeric monoclonal antibody cetuximab
(Erbitux), which blocks EGFR ligand binding, has been shown
to improve the survival of patients with metastatic colon cancer
and has shown efficacy in patients with non-small cell lung can-
cer (NSCLC) (Baselga and Arteaga, 2005), clinically validating
the approach of targeting EGFR ligands to treat these cancers.
The EGFR tyrosine kinase inhibitors gefitinib (Iressa) and erloti-
nib (Tarceva) have also shown efficacy in patients with NSCLC
(Herbst et al., 2004), particularly in a subgroup of patients that
have mutations in the EGFR kinase domain that are more sus-
ceptible to inhibition by these molecules (Lynch et al., 2004;
Paez et al., 2004; Pao et al., 2004). Unlike other growth factor
receptors, many of these mutant EGFR proteins are not consti-
tutively active and are still sensitive to ligand stimulation (Lynch
et al., 2004; Riemenschneider et al., 2005).
Despite the efficacy of the antibodies and kinase inhibitors tar-
geting the EGFR pathway, the majority of patients do not expe-
rience long-termbenefit from these therapies. Data frompreclin-
ical models suggest that activation of alternative ErbB pathways
can bypass specific blockade and that combination therapies
are more effective than any single agent against the EGFR path-
way (Huang et al., 2004; Matar et al., 2004; Normanno et al.,
2002). Alternative strategies targeting the ErbB pathway are still40needed. A potent ADAM inhibitor would fulfill this role by control-
ling the availability of multiple ErbB ligands and could potentially
be used in combination with various anti-ErbB agents. It should
be noted that many of the existing broad-spectrum metallopro-
tease inhibitors, such asmarimastat, inhibit not only MMPs (ma-
trix metalloproteinases) but also ADAMs in vitro (Roghani et al.,
1999) and thereby prevent the processing of multiple ErbB li-
gands (Dong et al., 1999; O-Charoenrat et al., 2002). However,
their clinical development has been hampered by side effects,
many of which are likely due to MMP inhibition (Coussens
et al., 2002; Zhou et al., 2005). In addition, it remains to be tested
whether a selective ADAM inhibitor can also inhibit multiple ErbB
ligand processing and signaling.
Since the importance of the ErbB pathway and the molecular
understanding of its sensitivity to EGFR antagonists are best
documented in NSCLC, and NSCLC is the leading cause of
death from cancer in both men and women in the United States
(Jemal et al., 2005), we focused our current study in this disease
setting and tried to address the following questions. Does the
activation of alternative ErbB signaling pathways, specifically
those involving heregulin and HER3, lead to resistance to anti-
EGFR agents such as gefitinib in NSCLC? Which ADAM should
we target to inhibit the HER3 pathway and overcome heregulin-
dependent gefitinib resistance? Can we find an ADAM inhibitor
that is more selective than marimastat but still capable of inhib-
iting cleavage of multiple ErbB ligands? Can the selective ADAM
inhibitor be used in combination with gefitinib and chemothera-
peutic agents in NSCLC?
Results
A HER3 autocrine stimulatory loop in NSCLC
To test our hypothesis that the heregulin-HER3 autocrine loop
may be involved in human lung tumorigenesis, we examined
the expression of heregulin and HER3 in NSCLC tumors using
antibodies against heregulin and HER3. Fourteen fresh NSCLC
tumors, of which seven were squamous cell carcinomas (cases
1, 2, 4, 5, 7, 9, and 10) and seven were adenocarcinomas (cases
3, 6, 8, 11, 12, 13, and 14), and their autologous-matched non-
malignant lung tissues were obtained from patients undergoing
tumor resection as part of their treatment. As shown in Figure 1,
nine out of fourteen freshly resected NSCLC tissues presentedCANCER CELL JULY 2006
A R T I C L EFigure 2. Heregulin contributes to gefitinib resis-
tance in NSCLC cell lines
A: Heregulin expression correlates with gefitinib
insensitivity in NSCLC cell lines. Microarray ex-
pression data are presented on 42 NSCLC cell
lines, including five gefitinib-sensitive cell lines
(IC50 < 0.4 mM, highlighted in yellow) and 37 ge-
fitinib-insensitive cell lines (IC50 > 4.0 mM, high-
lighted in orange). Calu-3 and H820 cell lines
have IC50s of 1.0 and 3.0 mM, respectively, and
their microarray data are not shown. Log ratios
and p values are shown on the left. Expression
levels are color coded such that darker colors
correspond to higher levels.
B: Effects of soluble heregulin on the gefitinib
sensitivities of five gefitinib-sensitive cell lines.
Shown are gefitinib IC50s with error bars (SD; n =
8) of various cell lines with and without heregulin
(50 ng/ml), and the IC50 shift caused by adding
heregulin. While H3255 and HCC827 have geno-
mic amplification of EGFR, HCC2279, HCC2935,
and HCC4006 do not.
C: Addition of soluble heregulin makes the gefiti-
nib-sensitive cell line HCC2935 more than 60-fold
less sensitive to gefitinib. Cells with or without
heregulin (50 ng/ml) added were treated for
96 hr in the presence of increasing concentra-
tions of gefitinib, and their growth was then
measured using the MTS assay and plotted as
a percentage of the growth of untreated cells
(control) with error bars (SD; n = 3).
D: Heregulin-induced HER3 and Akt phosphory-
lation can bypass the gefitinib blockade in
HCC2935. HCC2935 cells were serum starved
for 6 hr and then grown in the presence of vari-
ous concentration of gefitinib for 12 hr followed
by heregulin (50 ng/ml) or EGF (50 ng/ml) stimula-
tion for 30 min. Western blots are shown for phos-
pho- and total HER3, ERK1/2, and Akt.with increased expression of heregulin compared with nonma-
lignant lung tissue control, while seven out of fourteen had
increased expression of HER3. To show directly that the HER3
autocrine stimulatory loop was active in NSCLC, we used a
phosphospecific antibody against Tyr-1289 of HER3, which is
phosphorylated upon heregulin binding and is in a YXXM motif
that participates in direct signaling to PI3 kinase (Kim et al.,
1994). As shown in Figure 1, at least five out of fourteen freshly
resected NSCLC tissues had activated HER3, and all of them
coexpressed both HER3 and heregulin, suggesting the exis-
tence of a HER3 autocrine stimulatory loop in NSCLC.
Heregulin and HER2-mediated HER3 activation correlate
with insensitivity to gefitinib among NSCLC cell lines
Because the clinical significance of HER3 activation in NSCLC
is currently unknown, we used NSCLC cell lines to ask whetherCANCER CELL JULY 2006HER3activation could contribute todrug resistance.We recently
evaluated gene expression in 44 different NSCLC cell lines using
microarrays and determined their in vitro sensitivity to gefitinib
(L.G., M.P., I. Sekine, S. Zachariah, C. Lam, M. Wong, D. Beer,
W. Gerald, A.F.G., and J.D.M., unpublished data; M.P., L.G.,
and J.D.M., unpublished data). To examine the effects of ErbB
ligands and receptors on gefitinib sensitivity, we compared their
mRNA levels against gefitinib sensitivity across the 44 NSCLC
cell lines. Among various genes examined (Figure 2A), only the
expression of heregulin (HRG) significantly correlatedwith insen-
sitivity togefitinib (p<0.001). Interestingly,HER3expressionvery
weakly correlatedwith gefitinib sensitivity (p =0.135), suggesting
that it is the heregulin-induced HER3 activation rather than the
level of HER3 expression that leads to gefitinib insensitivity.
Upon ligand binding, HER3 can form heterodimers with both
EGFR and HER2. To further examine our hypothesis, we added41
A R T I C L EFigure 3. Characterization of A549 as a HER3 autocrine line and its dependence on ADAM17
A: Effects of anti-HER3 antibody and gefitinib on phosphorylation of HER3 and downstream Akt and ERK1/2 in A549. A549 cells were serum starved for 6 hr and
then grown with various treatments for 48 hr. Western blots are shown for phospho- and total HER3, Akt, and ERK1/2. Phospho- and total Akt and HER3 signals
were quantitated, and the ratios are presented relative to control.
B: Both EGFR and HER2 are required for heregulin-dependent HER3 signaling in A549. A549 cells were transfected with appropriate siRNAs twice, serum starved
for 48 hr, and then harvested for Western blot.
C: ADAM17 is important for heregulin-dependent HER3 signaling in A549. siRNA experiments were performed as in B.soluble heregulin to five gefitinib-sensitive cell lines: all of them
have EGFR mutations, but none of them expresses significant
levels of heregulin (Figure 2A). Among them, three cell lines with-
out EGFR amplification (HCC2935, HCC2279, and HCC4006)
showed increased resistance to gefitinib after heregulin was
added (Figure 2B). The change is particularly dramatic for
HCC2935, the only gefitinib-sensitive line in our study that ex-
presses more HER2 than EGFR (Figure 2A; M.P., L.G., and
J.D.M., unpublished data). As shown in Figure 2C, the addition
of soluble heregulin shifts the IC50 of gefitinib from 110 nM
to 6.71 mM. The addition of soluble EGF at similar concentra-
tions did not have much impact on gefitinib sensitivity in the
HCC2935 cell line (data not shown). Furthermore, while the con-
stitutive Akt phosphorylation and EGF-induced Akt phosphory-
lation in HCC2935 are sensitive to gefitinib, heregulin-induced
HER3 phosphorylation and Akt phosphorylation are not inhibit-
able by gefitinib at concentrations up to 5 mM (Figure 2D). On
the contrary, H3255 and HCC827, both of which have genomic
amplification of the EGFR locus (Tracy et al., 2004; Amann et al.,
2005) and presumably predominant EGFR homodimers or het-
erodimers, do not change their sensitivity to gefitinib after the
addition of either heregulin (Figure 2B) or EGF (data not shown).
Since gefitinib is selective toward EGFR, heregulin-dependent
HER3 activation may bypass gefitinib inhibition when HER2-
HER3 is one of the major heterodimers present.
A549 is an example of a HER3 autocrine line that is
insensitive to gefitinib and dependent on EGFRandHER2
for HER3 signaling
Among the few NSCLC cell lines expressing high levels of here-
gulin, HER3, and HER2 (Figure 2A), A549 has been previously
suggested to be a heregulin-HER3 autocrine line (Gollamudi
et al., 2004). We confirmed that A549 has constitutively active
HER3 under serum-free conditions (Figure 3A). To further char-
acterize A549 as a heregulin-HER3 autocrine line, we exoge-
nously added anti-HER3 antibody that can block heregulin42binding to HER3. As shown in Figure 3A, blocking of heregulin
binding inhibits the constitutive phosphorylation of HER3 as
well as Akt downstream in the pathway, suggesting that heregu-
lin functions as an autocrine growth factor in A549. On the other
hand, the constitutive ERK activity in A549 was not affected
by blocking heregulin binding and may be mediated by mutant
K-ras (Valenzuela and Groffen, 1986). In contrast to the anti-
HER3 antibody, gefitinib does not have a significant impact on
this autocrine pathway at the concentrations tested (Figure 3A),
implicating the role of HER2 in this autocrine loop as well. This
hypothesis is supported by RNA interference experiments:
knockdown of either EGFR or HER2 is not sufficient to signifi-
cantly inhibit the HER3 autocrine loop in A549, while knocking
down both leads to a dramatic reduction in both HER3 and
Akt phosphorylation (Figure 3B).
ADAM17 protein correlates with HER3 activation in
NSCLC and is required for HER3 signaling in A549 cells
ADAM17 was suggested to be a major sheddase for heregulin
(Horiuchi et al., 2005) and, therefore, could contribute to the
autocrine activation of HER3 in NSCLC. To study the role of
ADAM17 in NSCLC, we analyzed the expression of ADAM17
in NSCLC tumors using antibodies against ADAM17. As shown
in Figure 1, ten out of fourteen freshly resected NSCLC tissues
had increased expression of ADAM17 compared with autolo-
gous-matched nonmalignant lung tissue control. In addition,
there was a high rate of activation of HER3 in tumors with in-
creased ADAM17 levels compared with those tumors with low
ADAM17 expression (p % 0.05). Although many patients have
similar ADAM10 protein expression in tumors versus control,
several of them (including cases 2, 4, and 11) have a higher ratio
of the processed versus the proform of ADAM10 in the tumor
samples, indicative of ADAM10 activation in these patients.
However, ADAM10 activation does not correlate with HER3 ac-
tivation (Figure 1), and neither do the other ADAMs previouslyCANCER CELL JULY 2006
A R T I C L Eimplicated in ErbB ligand processing (Figure S1 in the Supple-
mental Data available with this article online).
To test if either ADAM17 or ADAM10 is involved in HER3
autocrine signaling in A549, we used RNA interference to selec-
tively knock down the expression level of either protein. As
shown in Figure 3C, ADAM10 knockdown had no significant
effect on HER3 or Akt activity in A549, whereas knockdown of
ADAM17 mirrored the effect of the anti-HER3 antibody and
affected both HER3 and Akt phosphorylation. On the other
hand, knocking down ADAM9 or ADAM15, two ADAMswith sig-
nificant expression in A549, had no apparent effect on HER3 au-
tocrine signaling in A549 cells (Figure S2). Together, these re-
sults support ADAM17 as a potential target for modulating the
HER3 autocrine loop in NSCLC.
Inhibition of ADAM protease activity prevents the
cleavage of heregulin and EGFR ligands
To study the impact of ADAM inhibition on shedding of heregulin
as well as EGFR ligands and its potential to inhibit multiple
ErbB pathways in the clinic, we identified a selective, orally bio-
available small molecule inhibitor, INCB3619 (Figure 4A; Liu
et al., 2006), which has potent inhibitory activity against both
ADAM10 and ADAM17 and a better selectivity profile than
marimastat across a panel of metalloproteases (Figure 4B).
The selectivity and inhibitory activity of the structurally related
molecules INCB8765, INCB4298, and INCB3420 are also pre-
sented in Figure 4B. Since INCB3619 has some MMP2 and
MMP12 inhibitory activities, INCB3420, which lacks ADAM10
and ADAM17 activity, was identified as a negative control. As
shown in Figure 4C, the dual ADAM inhibitor INCB3619 inhibits
heregulin cleavage with an IC50 value of 0.24 mM. In addition
to heregulin, INCB3619 can prevent the cleavage of TGFa,
HB-EGF, AR, EGF (Figure 4D), and HER2 (Liu et al., 2006) similar
to marimastat. In agreement with data obtained from studies us-
ing knockout cells (Sahin et al., 2004; Horiuchi et al., 2005), we
found that the ADAM17-selective inhibitor INCB4298 inhibits
the shedding of heregulin, TGFa, HB-EGF, and AR, whereas
the ADAM10-selective inhibitor INCB8765 blocks EGF ligand
processing. These results suggest that pharmacological inter-
vention of ADAM activity has a similar effect to knocking out
the protein. In contrast, the MMP2/12-active, ADAM10/17-inac-
tive INCB3420 did not block the shedding of any tested ErbB
ligands (Figure 4D), further strengthening the argument that it
is ADAMs, particularly ADAM17 and ADAM10, not MMPs, that
are involved in ErbB ligand shedding. To maximize the effect
on ErbB ligand processing and signaling, the dual inhibitor
INCB3619 was chosen for further characterization.
INCB3619 abrogates heregulin activation and heregulin-
dependent HER3 signaling and increases gefitinib
sensitivity in A549 cells
To examine the effect of ADAMs and their inhibitors on the func-
tional release and activation of heregulin, conditioned medium
from A549 cells treated with inhibitors or transfected with
siRNAs was added to the medium of a reporter cell, MCF-7,
which expresses HER3 but insignificant amount of heregulin.
As shown in Figure 5A, INCB3619 inhibits the heregulin release
and activation, measured by HER3 activation in MCF-7, similar
to the effect of ADAM17 siRNA. The ADAM17-selective inhibitor
INCB4298 showed a similar effect, whereas the ADAM10-selec-
tive inhibitor INCB8765 or ADAM10 siRNA had no effect. As aCANCER CELL JULY 2006control, the heregulin neutralizing antibody and the anti-HER3
antibody can block the activity in A549 conditioned medium
(Figure S3), confirming that it is the heregulin activity that is mea-
sured in the MCF-7 reporter cell assay.
Similar to antibody blockage of heregulin binding to HER3,
INCB3619 can inhibit the heregulin-dependent HER3-Akt path-
way but not ERK activity in A549 cells; the ADAM17-selective
inhibitor INCB4298 has a similar effect (Figure 5B). Addition of
soluble heregulin can bypass the inhibition, consistent with the
hypothesis that heregulin cleavage is the target of inhibition.
As controls, the ADAM10-selective inhibitor INCB8765 (Fig-
ure 5B) and the ADAM10/17-inactive inhibitor INCB3420 (data
not shown) did not have a significant impact on this pathway.
Since a HER3 autocrine mechanism is believed to contribute
to the gefitinib insensitivity in A549 cells, we tested whether
INCB3619 can sensitize A549 cells to gefitinib. As shown in Fig-
ure 5C, INCB3619 shifts the IC50 of gefitinib in A549 cells quite
significantly, further supporting the role of a heregulin-HER3
Figure 4. Selective ADAM inhibitor INCB3619 inhibits the cleavage of here-
gulin and EGFR ligands
A: Chemical structure of INCB3619.
B: Selectivity and inhibition profile of INCB3619 and related ADAM inhibitors
against a panel of metalloproteases.
C: INCB3619 inhibits the heregulin cleavage measured by ELISA assay. Data
are presented as mean percentage inhibition values with error bars (SD;
n = 4).
D: Effects of several ADAM inhibitors on the cleavage of various ErbB ligands.
IC50s are presented here.43
A R T I C L EFigure 5. ADAM inhibitors block the activation of
heregulin and HER3 autocrine signaling in A549
A: Effect of ADAM inhibition or knockdown on
the heregulin activation from A549 measured
by the MCF-7 reporter assay. From left: control,
medium alone; DMSO, conditioned medium
from A549 treated with DMSO; 1 mM or 10 mM,
conditioned medium from A549 treated with dif-
ferent compounds at indicated concentrations.
Far right panel: control, medium alone; control,
ADAM10, or ADAM17, conditioned medium
from A549 transfected with control siRNA,
ADAM10 siRNA, or ADAM17 siRNA. Phospho-
and total HER3 signals were quantitated, and
the ratios are presented relative to control.
B: Effect of ADAM inhibition on heregulin-depen-
dent HER3 signaling in A549 cells. A549 cells
were serum starved for 4 hr before being treated
with indicated concentrations of INCB3619,
INCB8765, and INCB4298 for 72 hr. For INCB3619
and INCB4298, 50 ng/ml of heregulin was also
added to reverse the signaling effect.
C: INCB3619 sensitizes A549 cells to gefitinib.
A549 cells in serum-free medium were treated
with various concentrations of gefitinib and
INCB3619 for 96 hr, and their viability was mea-
sured and plotted as a percentage of viable
cells relative to DMSO mock treatment. Data
are presented as mean values with error bars
(SD; n = 3).autocrine mechanism in gefitinib insensitivity; however, we can-
not rule out the possibility that the K-ras mutation in A549 also
contributes to the gefitinib resistance.
INCB3619 induces apoptosis in A549 cells and has
antitumor activity in the A549 xenograft model
Consistent with its impact on the Akt pathway, INCB3619 can in-
duce apoptosis in A549 cells (Figure 6A). The addition of heregu-
lin can reverse the effect, suggesting that its effects are most
likely pathway specific. Since INCB3619 impacts the survival
branch of the ErbB pathway in A549, we reasoned that our inhib-
itor should synergize with a cytotoxic agent in this cell line. As
shown in Figure 6A, INCB3619 can reduce the apoptotic thresh-
old for paclitaxel in A549 cells.
To extend these observations, we determined whether
INCB3619 can impact tumor growth as a single agent and
when combined with paclitaxel in the A549 xenograft model.44As shown in Figure 6B, there is a significant tumor growth inhi-
bition and delay (p = 0.016, compared with control group) at
a dose of 60 mg/kg/day, a dose that produces a steady-state
plasma drug level of nearly 1.5 mM, based on historical pharma-
cokinetic data. When adjusted for serum protein binding, the
effective drug concentration is approximately 0.5 mM, consis-
tent with the in vitro IC50 for heregulin cleavage inhibition by
INCB3619 (Figure 4C). In these studies, the compound itself
was well tolerated, based on clinic observations and body
weight changes in the drug-treated mice (data not shown). Fur-
thermore, paclitaxel alone (20 mg/kg, every 4 days, four doses
in total) had a moderate antitumor activity (p = 0.03), while
INCB3619 (50 mg/kg/day) had a weak activity (p = 0.2) in the
A549 xenograft model in CD-1 nu/numice (Figure 6C). The lower
activity of the compound alone observed in this experimental
setting may be due to less drug exposure in CD-1 nu/nu mice
compared to BALB/c nu/nu mice used in the previousCANCER CELL JULY 2006
A R T I C L Eexperiment (Figure 6B). Nevertheless, the combination of
INCB3619 and paclitaxel significantly inhibited tumor growth
(p = 0.0001), with no additional toxicity observed over that
seen with paclitaxel alone (data not shown). Together, these re-
sults suggest that the ADAM inhibitor INCB3619 inhibits the ge-
fitinib-resistant HER3 autocrine mechanism, possesses antitu-
mor activity in vivo, and sensitizes tumors to chemotherapeutic
agents.
Figure 6. INCB3619 induces apoptosis in A549 cells and has antitumor activ-
ity in the A549 xenograft model
A: INCB3619 can increase apoptosis and reduce the apoptotic threshold for
paclitaxel in A549. Shown are the mean percentages of apoptosis with error
bars (SD; n = 3).
B: The effect of INCB3619 on the growth of A549 human NSCLC xenograft
in BALB/c nu/nu mice. INCB3619 was administered subcutaneously using
ALZET osmotic pumps at 30 or 60 mg/kg/day for 14 days. The experiment
has been repeated twice, and one set of data is shown here. Shown are
mean tumor volumes with error bars (SEM; n = 7).
C: Combination effect of INCB3619 and paclitaxel in treatment of A549
human NSCLC xenografts in CD-1 nu/nu mice. INCB3619 was administered
subcutaneously using ALZET osmotic pumps at a dose of 50 mg/kg/day for
14 days. Paclitaxel was administered intravenously at a dose of 20 mg/kg,
every 4 days for a total of four injections. Shown are mean tumor volumes
with error bars (SEM; n = 7).CANCER CELL JULY 2006INCB3619 inhibits the EGFR ligand signaling in the EGFR
autocrine cell line NCI-H1666 and sensitizes it to gefitinib
The EGFR autocrine mechanism can be targeted by anti-EGFR
agents such as gefitinib and cetuximab. However, many NSCLC
lines expressing EGFR ligands, especially those with wild-type
EGFR, are not particularly sensitive to gefitinib (Figure 2A). To
study the effect of our selective ADAM inhibitor on EGFR signal-
ing and gefitinib sensitivity, we searched for an EGFR ligand-
dependent NSCLC autocrine cell line. NCI-H1666 is among
those putative EGFR-driven autocrine cell lines with wild-type
EGFR and limited sensitivity to gefitinib and cetuximab (Tracy
et al., 2004; Amann et al., 2005; Mukohara et al., 2005). Using
various siRNAs and C225 (the murine version of cetuximab),
we indeed found that NCI-H1666 is an ADAM17-mediated,
EGFR ligand-dependent autocrine NSCLC cell line with interme-
diate sensitivity to gefitinib (Figure S4).
We studied the impact of ADAM inhibitors on the functional
release and activation of EGFR ligands from NCI-H1666 cells,
which express TGFa, AR, and EPR (Figure 2A), using an A431
reporter cell assay. As shown in Figure 7A, INCB3619 inhibits
EGFR ligand activation, as measured by EGFR phosphorylation
on Tyr-1173 in A431. Similar to C225, INCB3619 inhibits ligand-
dependent activation of the EGFR-ERK pathway in NCI-H1666
cells (Figure 7B); addition of soluble TGFa can bypass this inhi-
bition. As a control, the ADAM10-selective inhibitor INCB8765
does not have a significant impact on either ligand activation
or EGFR signaling, while the ADAM17-selective inhibitor
INCB4298 has a similar effect to INCB3619. These results
suggest that INCB3619 abrogates EGFR autocrine signaling in
NCI-H1666, most likely through inhibiting ADAM17-mediated
processing of several EGFR ligands.
INCB3619 inhibits the proliferation of NCI-H1666 cells under
serum-free conditions (Figure S5). Since both INCB3619 and
gefitinib inhibit NCI-H1666 proliferation, presumably by blocking
targets at different levels in the same pathway, we tested
whether the inhibition of EGFR ligand cleavage can sensitize
NCI-H1666 to gefitinib. Figure 7C shows the combined effect
of INCB3619 and gefitinib: under serum-free condition, 0.53 mM
of gefitinib is needed to inhibit proliferation by 50%; with 2 mM
INCB3619, 6-fold less (0.087 mM) gefitinib achieves an equiva-
lent effect. Using the concentration near the IC50 for each
compound, we tested the combined effect of the sheddase
inhibitor and gefitinib on ErbB signaling. As shown in Figure 7D,
both 2 mM INCB3619 and 0.5 mM gefitinib significantly reduced
ERK phosphorylation, while the combined effect is even more
dramatic. Our results with NCI-H1666 cells suggest that the
ADAM inhibitor INCB3619 can inhibit EGFR signaling and be
used in combination with other anti-EGFR agents.
Discussion
Cancer cells synthesize and secrete various growth factors and
can also express their cognate receptors, allowing the secreted
growth factors to stimulate tumor growth through autocrine
mechanisms (Barnes and Sato, 1980; Carpenter and Cohen,
1990; Osborne and Arteaga, 1990; Sporn and Todaro, 1980).
EGFR and its ligands form one of the best-defined autocrine
growth loops in human tumors (Salomon et al., 1995), and their
coexpression correlates with aggressive disease and poor
prognosis in several types of tumors, including NSCLC (Salo-
mon et al., 1995; Umekita et al., 2000; Tateishi et al., 1990;45
A R T I C L EFigure 7. INCB3619 inhibits EGFR autocrine signaling in NCI-H1666 and sensitizes it to gefitinib
A: INCB3619 inhibits EGFR ligand activation from NCI-H1666 measured by the A431 reporter assay. Left panel: control, buffer; TGFa, 10 ng/ml TGFa; TGFa + C225,
TGFa added to the A431 cells pretreated with C225 for 10 min. Right panel: control, medium alone; DMSO, conditioned medium from NCI-H1666 treated with
DMSO for 48 hr; 2 mM 3619 or 10 mM 3619, conditioned medium from NCI-H1666 treated with INCB3619 at indicated concentrations for 48 hr. Phospho- and total
EGFR signals were quantitated, and the ratios are presented relative to control.
B: INCB3619 inhibits EGFR ligand-dependent signaling in NCI-H1666 cells. A549 cells were serum starved for 4 hr before being treated with indicated concen-
trations of various compounds for 72 hr. For INCB3619, 50 ng/ml of TGFa was added to reverse the signaling effect.
C: INCB3619 sensitizes NCI-H1666 cells to gefitinib. NCI-H1666 cells in serum-free medium were treated with various concentrations of gefitinib and INCB3619 for
72 hr, and their viability was measured and plotted as a percentage of viable cells relative to DMSO mock treatment. Data are presented as mean values with
error bars (SD; n = 3).
D: Combination effect of INCB3619 and gefitinib on the EGFR autocrine signaling. NCI-H1666 cells in serum-free medium were treated with DMSO alone, 2 mM
INCB3619, 2 mM INCB3619 in the presence of 50 ng/ml TGFa, 0.5 mM gefitinib, or 0.5 mM gefitinib plus 2 mM INCB3619. Phospho- and total ERK1/2 signals were
quantitated, and the ratios are presented relative to control.Gorgoulis et al., 1992). Based on these observations, the con-
cept has developed that preventing ligand binding to EGFR,
just like inhibiting EGFR kinase activity, should inhibit the prolif-
eration of epithelial-derived tumor cells (Mendelsohn, 1997).
With various anti-EGFR antibodies having demonstrated clinical
activity in cancer, this hypothesis has gained considerable sup-
port (Baselga and Arteaga, 2005). In this paper, we discuss
a complementary approach that prevents the release and acti-
vation of ligands for both EGFR and HER3 (Figure 8).
One potential mechanism of resistance to anti-EGFR agents
is the activation of ligands that target the alternate ErbB recep-
tors. We demonstrate here the existence of a HER3 autocrine
stimulatory loop in NSCLC using tissue samples. Although
HER3 expression has been shown to correlate with gefitinib sen-
sitivity among NSCLC cell lines (Engelman et al., 2005), genomic
gain of HER3 is not associated with increased sensitivity to46gefitinib in advanced NSCLC patients (Cappuzzo et al., 2005).
The lack of a strong association with gefitinib sensitivity is not
surprising because HER3 lacks kinase activity and only signals
in the context of a receptor heterodimer upon ligand binding.
Therefore, thebestway to evaluate the impact ofHER3 is in com-
bination with its ligand and partnering ErbB receptors, particu-
larly EGFR and HER2. In our study, we found that HER3 expres-
sion very weakly correlates with gefitinib sensitivity, while the
expression of heregulin shows a significant correlation with gefi-
tinib insensitivity. Subsequent studieswithNSCLCcell lines sug-
gested that heregulin-dependent HER3 activation can bypass
the inhibition of gefitinib, and presumably other EGFR specific
agents as well, when HER2-HER3 is one of the major hetero-
dimers present.
ADAMsmight be attractive targets for the treatment of cancer
due to their role in shedding ErbB ligands (Blobel, 2005; ZhouCANCER CELL JULY 2006
A R T I C L EFigure 8. The ErbB signaling network and sites of
therapeutic intervention
ADAM-mediated proteolytic cleavage releases
the ligands, which bind to the ErbB receptor
through autocrine and/or paracrine mecha-
nisms and lead to receptor dimerization, trigger-
ing multiple downstream signaling cascades, in-
cluding Ras-ERK and PI3K-Akt pathways. While
cetuximab blocks the binding of several EGFR
ligands to EGFR, gefitinib inhibits EGFR kinase
activity. On the other hand, small molecule in-
hibitors of ADAM proteases, such as INCB3619,
inhibit the availability of multiple ErbB ligands,
including EGFR ligands and heregulin.et al., 2005).We found that the ADAM17 protein level is elevated,
while the activated form of ADAM10 is present at higher levels
in NSCLC. Further, we found a correlation between ADAM17
protein level and HER3 activation in NSCLC, similar to that ob-
served between ADAM17 overexpression and EGFR activation
in human breast cancers (Borrell-Pages et al., 2003). Our studies
with both siRNAs and ADAM inhibitors suggest that ADAM17 is
important for both heregulin-dependent ErbB signaling in A549
cells and EGFR ligand-dependent ErbB signaling in NCI-H1666
cells, further validating ADAM17 as a drug target in NSCLC.
TIMP3, a negative regulator of ADAMs, including ADAM17,
was found to be downregulated at the mRNA level in NSCLC
(data not shown), at least partially due to aberrant TIMP3 pro-
moter methylation (Bachman et al., 1999; Zochbauer-Muller
et al., 2001). Overexpression of TIMP-3,whichwouldbeexpected
to reduce ErbB ligand shedding, has been shown to suppress
tumor growth in vivo (Bian et al., 1996); therefore, addition of
an ADAM inhibitor would essentially restore the negative regula-
tion normally exercised by TIMP-3.
Compared with many available metalloprotease inhibitors,
such as marimastat, the ADAM inhibitor INCB3619 is more se-
lective for the ADAM family, is not active against many members
of the MMP family of metalloproteases, and has a far superior
safety profile in preclinical models, including the lack of muscu-
loskeletal side effects (J.S.F., E.C., M. Hansbury, X. Liu, X. Gu,
M. Pan, B.-B.S.Z., G.Y., Q. Wang, Y.L., S. Thomas, J. Grandis,
J. Zhuo, W.Y., R.C.N., S.M.F., P.A.S., and K.V., unpublished
data). One consideration associated with utilizing an ADAM17
and ADAM10 dual inhibitor is that ADAM10 has also been sug-
gested to be involved in ErbB ligand shedding under certain cir-
cumstances (Prenzel et al., 1999; Sahin et al., 2004; Yan et al.,
2002). In addition, only dual inhibitors, not the more selective in-
hibitors, have inhibited the shedding and activation of all ligands
tested in our study. Although both NSCLC ErbB autocrine lines
that we studied depend on ADAM17 for ligand-dependent sig-
naling, we cannot rule out the possibility that other NSCLC
ErbB autocrine lines or autocrine mechanisms in certain NSCLC
patients might rely on ADAM10, particularly since ADAM10 isCANCER CELL JULY 2006also activated in NSCLC. In addition, the dual ADAM inhibitor
can affect ErbB signaling pathways during tumor progression
by inhibiting ErbB receptor cleavage (Liu et al., 2006). An addi-
tional benefit of targeting ADAM10 could come from its role in
angiogenesis and/or metastasis (Zhou et al., 2005).
Although we focused our in vitro studies on autocrine activa-
tion of various ErbB pathways, paracrine mechanisms also exist
in xenograft models and in patients, although their contribution
is less clear in most cases. Since the same proteases are in-
volved in these processes, we expect that an ADAM inhibitor
will inhibit both potential sources of ligand. In some model
systems,membrane bound ErbB ligands can also engage in jux-
tacrine signaling (Brachmann et al., 1989; Wong et al., 1989),
which was recently shown to require ADAM activity as well
(Borrell-Pages et al., 2003). Consistent with this hypothesis,
INCB3619 inhibits heregulin and EGFR ligand-mediated ErbB
signaling, even under high-cell density conditions, which favor
juxtacrine signaling (data not shown).
Inhibition of the ErbB ligand processing step has different
functional consequences in different systems. In A549 cells,
INCB3619 can inhibit theHER3andAkt activity, similar to knock-
ing down both EGFR and HER2 in this cell line. Importantly,
INCB3619 can sensitize A549 cells to gefitinib and paclitaxel
and has antitumor activity alone and in combination with pacli-
taxel in an A549 xenograft model. NCI-H1666 cells, although
possessing wild-type EGFR, have intermediate sensitivity to
gefitinib.We demonstrate here that INCB3619 inhibits cell prolif-
eration in theNCI-H1666 cell line and sensitizesNCI-H1666 cells
to gefitinib, potentially translating to improved efficacy of gefiti-
nib among those NSCLC patients with stable disease or partial
response to gefitinib in the clinic. On the other hand, INCB3619
does not affect cell proliferation or ErbB signaling in nontrans-
formed lung epithelial cells (Figure S6) and is inactive in a xeno-
graftmodel (MDA-MB-231) that is notdependent onErbBsignal-
ing for growth (J.S.F., E.C., M. Hansbury, X. Liu, X. Gu, M. Pan,
B.-B.S.Z., G.Y., Q. Wang, Y.L., S. Thomas, J. Grandis, J. Zhuo,
W.Y., R.C.N., S.M.F., P.A.S., andK.V., unpublisheddata), further
demonstrating its selectivity.47
A R T I C L EIn summary, the therapeutic use of ADAM inhibitors, such as
INCB3619, has the potential to control the availability of numer-
ous ErbB ligands and overcome gefitinib resistance caused by
the HER3 autocrine mechanism, and thereby offer important
advantages over existing anti-EGFR strategies by abrogating
the ability to signal through multiple ErbB pathways (Figure 8).
Clearly, strategies targeting ADAMsmight be an important com-
plement to existing anti-ErbB approaches and could potentially
be used in combination with various anti-ErbB and chemother-
apeutic agents. Current ongoing clinical evaluation of our selec-
tive ADAM inhibitor is only beginning to address the scope of its
therapeutic potential in cancer treatment.
Experimental procedures
Cell lines
The cell lines described in this manuscript, except for A549, were established
at the National Cancer Institute (NCI-H series) or at the Hamon Center for
Therapeutic Oncology Research, University of Texas Southwestern Medical
Center (HCC series). These cell lines have been deposited for distribution in
the American Type Culture Collection (ATCC) (http://www.atcc.org/). A549
was obtained from ATCC.
Compounds
INCB3619, methyl (6S,7S)-7-[(hydroxyamino)carbonyl]-6-[(4-phenyl-3,6-dihy-
dropyridin-1(2H)-yl)carbonyl]-5-azaspiro[2.5]octane-5-carboxylate, INCB8765,
(1R,3S,4S)-3-[(hydroxyamino)carbonyl]-4-[(4-phenylpiperidin-1-yl)carbonyl]cy-
clohexyl pyrrolidine-1-carboxylate, INCB3420, (1S,2R)-N-hydroxy-2-({[4-(pyri-
din-4-yloxy)phenyl]sulfonyl}amino)cyclohexanecarboxamide, and relatedcom-
pound INCB4298 were synthesized by the Chemistry Department of Incyte
Corporation (Wilmington, DE), according to the methods described in U.S.
patent Ser. No. 60/543,501 and W.Y., J. Zhuo, D. Burns, M. Xu, F. Zhang,
and B. Metcalf (unpublished data). Gefitinib (Iressa) and paclitaxel (Taxol)
were purchased from Hanna Pharmaceuticals (Wilmington, DE). Marimastat
was obtained from British Biotech (Oxford, UK).
Antibodies and proteins
All antibodies were purchased from commercial sources as described
here: antibodies to ERK1/2 (p44/42 ERK kinase), phospho-ERK1/2 (Thr-
202/Tyr-204), Akt, phospho-Akt, cleavedCaspase-3 (Asp-175), EGFR, phos-
pho-EGFR (Tyr-1173), phospho-EGFR (Tyr-1068), HER2, phospho-HER3/
ErbB3 (Tyr-1289), and monoclonal, HRP-conjugated goat anti-rabbit IgG
and anti-mouse IgG were purchased from Cell Signaling (Beverly, MA).
Anti-HER3/ErbB3 (Ab6), used for Western blot, and anti-HER3/ErbB3 (Ab5,
CloneH3.105.5), used to block heregulin binding to HER3, were from Neo-
Markers (Fremont, CA). Anti-heregulin was from R&D systems (Minneapolis,
MN). Anti-ADAM17 was from Calbiochem (San Diego, CA). Anti-ADAM10
was from CHEMICON (Temecula, CA). Mouse monoclonal antibody C225
(EGFR Ab2) was from NeoMarkers (Fremont, CA).
Purified recombinant soluble heregulin, EGF, and TGFa were purchased
from R&D systems (Minneapolis, MN).
NSCLC tissue specimen preparation and Western blot analysis
Fresh NSCLC tissue and adjacent nonmalignant lung tissue from patients
undergoing curative primary resection of their tumors were collected at the
time of surgery and immediately snap-frozen in liquid nitrogen (UCSF IRB
approval #H8714-15319-07A). These tissue samples were kept at 2170ºC
in a liquid nitrogen freezer before use. T-PER tissue protein extraction re-
agent was purchased from Pierce (Rockford, IL) and used for preparation
of whole-cell extract.
Microarray analysis of NSCLC cell lines
RNA fluorescent labeling reaction and hybridization were performed using
the Affymetrix Gene Chips HG-U133A and HG-U133B according to the man-
ufacturer’s instructions (http://www.affymetrix.com/). The arrays consist of
22,283 (HG-U133A) and 22,645 (HG-U133B) probe sets, which together
amount to 23,583 unique genes based on Unigene build 173. Microarray
analysis was performed using Affymetrix Microarray Suite 5.0 and in-house48Visual Basic software MATRIX 1.26. Array data were median normalized,
and replicate genes were combined by averaging. Samples (or averages of
samples) were then compared against each other by calculating log ratios
for each gene, and statistical significance was presented as a p value calcu-
lated by Student’s t test. The microarray data have been uploaded to GEO
(Gene Expression Omnibus), and the accession number is GSE-4824.
RNA interference studies
All siRNAs were obtained from Dharmacon (Lafayette, CO). Sequences for
ADAM17 interfering RNAs (siRNA) were 50-GAACAAGUGUAAAUUAUUGU
U-30 (ADAM17 RNAi #1), 50-GAUCAUCGCUUCUACAGAUUU-30 (ADAM17
RNAi #2), 50-UAUGGGAACUCUUGGAUUAUU-30 (ADAM17 RNAi #3), 50-GA
GGAAGCAUCUAAAGUUUUU-30 (ADAM17 RNAi #4). To minimize nonspe-
cific effects of interfering RNAs, non-pathway-related siRNAs were used as
negative control. Transfection of siRNAs into cell lines was achieved using
Lipofectamine 2000 (Invitrogen, CA).
In vitro metalloprotease assays and ErbB ligand cleavage assays
Human MMPs, ADAM9, ADAM10, and ADAM33 were purchased from R&D
Systems (Minneapolis, MN), and partially purified porcine ADAM17 was ob-
tained from spleen as described (Moss et al., 1997). Both MMP and ADAM
assays were performed using substrates and conditions supplied by R&D
systems (Minneapolis, MN).
All ErbB ligand ELISA kits are from R&D Systems (Minneapolis, MN). Here-
gulin release wasmeasured by ELISA in supernatants collected from heregu-
lin-transfected CHO cells following stimulation with PMA (phorbol myristate
acetate) for 1 hr. HB-EGF release was measured in supernatants collected
from HB-EGF transfected CHO cells following stimulation with PMA for
45 min. The HB-EGF protein was tagged with alkaline phosphatase so that
levels could bemeasured using a chemiluminescent substrate. TGFa release
and AR release were measured by ELISA in supernatants collected from
HCT116 cells following stimulation with PMA for 30 min. EGF release was
measured by ELISA in supernatants collected fromH460 cells following stim-
ulation with PMA for 72 hr.
Reporter cell assay measuring the activation of ErbB ligand
A549orNCI-H1666 cells were grown in 75 cm2culture flasks inRPMImedium
containing 10% FCS until >50% confluency, washed, then treated in serum-
free medium. The medium was collected after 48 or 72 hr, concentrated by
a centrifugal filter device (Centriplus, Amicon, MA), then subjected to func-
tional testing using MCF-7 or A431 cells. For testing of heregulin activity,
MCF-7 cells (approximately 200,000 cells per well in 12-well plates) were
allowed to adhere in DMEM with 10% FCS overnight and then were growth
arrested for 8–16 hr in serum-free medium. Concentrated, conditioned
medium (100 ml) was added to the growth-arrested cells, cells were lysed
15min post-medium addition, and 20 mg of proteins were subjected toWest-
ern blotting for phosphorylated HER3. For testing of EGFR ligands, similar
experiments were performed usingNCI-H1666, and the activitywas detected
using phosphospecific antibody against Tyr-1173 of EGFR in A431 cells.
Ligand-dependent ErbB pathway analysis
A549 or NCI-H1666 cells were grown in 6-well plates in RPMI medium with
10% FCS until 30%–40% confluency and then treated in serum-free me-
dium. The cells were harvested 48–72 hr later forWestern blot. The intensities
of Western blot signals were quantitated using QuantiScan software (Biosoft,
Cambridge, UK).
Apoptosis assay by caspase immunostaining
Twenty thousand cells were seeded into each well of double-chamber slides
(Nalge Nunc International, IL), then treated in serum-free medium next day.
After 96 hr the cells were fixed with methanol at 220ºC for 10 min and then
blocked with PBS containing 1%BSA for 1 hr. Apoptotic cells were detected
by the cleaved caspase-3 (Asp-175) antibody (fluorescein conjugate) (Cell
Signaling Technology, MA); total cell numbers were measured by Hoechst
staining.
Proliferation assay
Cell growthwas evaluatedbyMTSassays (CellTiter 96AqueousOneSolution
Cell Proliferation Assay, Promega, WI) or cell viability assays (CellTiter-Glo
Luminescent Cell Viability Assay, Promega, WI). Cells were plated 24 hr prior
to addition of compounds, and assays were performed in 96-well plates.CANCER CELL JULY 2006
A R T I C L EXenograft studies in nude mice
Female BALB/c nu/nu or CD-1 nu/nu mice were obtained from Charles River
Laboratories (Wilmington, MA). When the mice were 7–8 weeks of age, each
mouse was inoculated with 1 3 107 tumor cells in 0.2 ml of medium subcu-
taneously in the right flank. The treatments were started at 7–10 days after
inoculation when the tumor size reached approximately 80–180 mm3, and
each treatment group contained seven animals. Tumor sizes were measured
weekly in two dimensions using a caliper, and the volume (mm3) was calcu-
lated using the formula V = 0.5a 3 b2, where a and b are the long and short
diameters of the tumor, respectively. The statistical significance was ana-
lyzed using the unpaired two-tailed Student’s t test. The standard error of
the mean (SEM) was calculated based on the standard deviation (SD) within
each group. All procedures involving animals were approved by Incyte Ani-
mal Care and Use Committee (ACUC).
Supplemental data
The Supplemental Data include Supplemental Experimental Procedures and
six supplemental figures and can be found with this article online at http://
www.cancercell.org/cgi/content/full/10/1/39/DC1/.
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